300 North Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

300 North Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-31,806	Closed	-$3.75M	–	86
2015 Q1	$3.75M	Buy	31,806 +4,299	+16%	+$515K	0.83%	53
2014 Q4	$3.27M	Buy	27,507 +7,694	+39%	+$867K	0.75%	62
2014 Q3	$2.23M	Sell	19,813 -937	-5%	-$89.2K	0.59%	70
2014 Q2	$1.96M	Buy	20,750 +1,562	+8%	+$110K	0.48%	77
2014 Q1	$1.36M	Buy	19,188 +1,408	+8%	+$112K	0.35%	78
2013 Q4	$1.32M	Sell	17,780 -20	-0.1%	-$1.39K	0.37%	78
2013 Q3	$1.35M	Buy	+17,800	New	+$1.42M	0.31%	97

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

300 North Capital's VRTX Position: Q2 2015 in Review

300 North Capital sold out of Vertex Pharmaceuticals (VRTX) in Q2 2015, closing a stake of 31,806 shares — an estimated $3.75M sold.

300 North Capital first reported a position in VRTX in Q3 2013 and held it in 7 quarters. The position peaked at $3.75M in Q1 2015. 501 funds tracked by Wall St. Rank hold VRTX as of Q2 2015.

300 North Capital reported no remaining Vertex Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
300 North Capital sold 31,806 Vertex Pharmaceuticals shares in Q2 2015, an estimated $3.75M.
300 North Capital first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 7 quarters.
300 North Capital's Vertex Pharmaceuticals position peaked at $3.75M in Q1 2015.
501 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2015.

Based on 300 North Capital's 13F filing for Q2 2015, filed 30 Jul 2015.